Last updated: May 31, 2026
COSELA (Trilaciclib) Supplier Landscape: Who Makes the Drug, Key Materials, and Contract Manufacturing Risks?
COSELA’s supply chain is tied to trilaciclib’s proprietary drug substance and finished-dose manufacturing under a branded-label commercial model in the US. Public disclosure on who supplies “finished goods” or who manufactures each upstream raw-material class for COSELA is not available in the provided inputs, so a supplier list cannot be produced without risking material errors.
What companies supply COSELA (trilaciclib) drug product and drug substance?
A complete supplier roster requires verified sourcing from primary records (eg, FDA registration and listing, Orange Book manufacturing/labeler details, CMOs in approvals, or procurement disclosures tied to COSELA’s NDA/BLA and dosage forms). The necessary identifiers (NDA number, dosage forms with strength, labeler/manufacturer on the US package insert, and FDA facility registrations) are not present in the provided information, so a precise supplier answer cannot be compiled.
How to identify COSELA labeler/manufacturer vs CMO
In US market practice, “labeler” and “manufacturer” can differ from the true commercial CMO. Supplier mapping should be built from:
- FDA Drug Registration and Listing labeler/manufacturer fields tied to COSELA
- Site-level manufacturing authorization (facility registration)
- NDA chemistry manufacturing controls (CMC) references
- Opaque “secondary supplier” relationships for excipients, intermediates, and APIs
No such facility-level data is provided here.
Which raw-material suppliers feed trilaciclib manufacturing?
Trilaciclib manufacturing includes API (drug substance) synthesis plus excipients and fill-finish inputs for the final infusion product (container closure system, sterile filtration, sterile water, buffers, and lyophilization or liquid-fill parameters depending on the labeled dosage form). Upstream “raw-material suppliers” are typically not public at the brand level and are often disclosed only in:
- CMC exhibits
- supplier qualification statements in regulatory filings
- procurement documents not public
The inputs needed to name actual suppliers are absent.
How does COSELA’s contract manufacturing footprint affect availability and risk?
Supply risk analysis depends on knowing:
- number of approved manufacturing sites for drug substance and drug product
- whether there are single-site dependencies
- whether there are post-approval manufacturing changes
- lead-time and scale-up constraints for sterile drug product
Those data points require facility and approval history, not supplied.
What is the Orange Book status of COSELA and does it affect suppliers?
Orange Book listings govern patent and exclusivity, not commercial sourcing. Supplier constraints can matter in practice where:
- manufacturing changes are constrained by patent claims tied to the drug substance or formulation
- biologics-style “reference product” supply is limited by IP or CMC exclusivity
No Orange Book entry set or exclusivity timeline is provided, so supplier impact cannot be mapped.
Do generic or biosimilar entry plans change COSELA supplier availability?
Competitive entry can shift supplier demand if:
- new labelers build supply chains for authorized generics or Paragraph IV challengers
- licensing agreements require shared facilities or tech transfers
To assess this, one needs the challenger list, settlement/launch agreements, and FDA approval outcomes, none of which are included here.
Key Takeaways
- COSELA supplier names (drug substance and drug product) and upstream raw-material suppliers cannot be stated from the information provided.
- A verified supplier list requires COSELA’s regulatory identifiers and facility-level manufacturing registration and listing details, which are not present in the inputs.
FAQs
-
How can COSELA’s manufacturer be confirmed for US distribution?
Confirm the labeler/manufacturer from FDA Drug Registration and Listing records tied to the COSELA package listing.
-
What documents best reveal API and CMO sourcing for trilaciclib?
NDA CMC exhibits, facility registration records, and approval supplements referencing manufacturing sites.
-
Do sterile fill-finish steps create supplier bottlenecks for COSELA?
Yes, if the dosage form is sterile and relies on limited aseptic capacity at approved CMO sites, but this requires site-specific approval data.
-
Can patent estates restrict changes to manufacturing suppliers for COSELA?
Patent claims can restrict process or formulation modifications in some cases, but supplier constraints still depend on the specific approved CMC and claimed subject matter.
-
Where do ex-US suppliers typically appear in COSELA sourcing?
They may appear through facility registrations outside the US or via importer-of-record data, but specific names require those records.
